DeepMed Research

NATIONAL INSTITUTE ON DRUG ABUSE AND ADDICTION

🇵🇰Pakistan

Country: 🇵🇰Pakistan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy of NicVAX in Smokers Who Want to Quit Smoking

Phase 2

Completed

Conditions: Smoking Cessation

Interventions: Biological: NicVAX conjugate vaccine
Biological: Placebo

First Posted Date: 2006-04-26

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 313

Registration Number: NCT00318383

Locations: 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States
🇺🇸
Tobacco Research Center, Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

and more 6 locations

Effects of Fatty Acid Supplementation on Substance Dependent Individuals

Phase 2

Completed

Conditions: Substance-related Disorders

Interventions: Drug: Pro-eicosapentaenoic acid (EPA)
Drug: Placebo
Drug: Pro-docosapentaenoic acid (DPA)

First Posted Date: 2006-04-10

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Registration Number: NCT00312455

Drug Use Prevention Among Girls Through a Mother-Daughter Intervention

Phase 3

Completed

Conditions: Adolescent Behavior

First Posted Date: 2006-04-03

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 2000

Registration Number: NCT00310258

Locations: 🇺🇸
Columbia University School of Social Work, New York, New York, United States

Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke

Phase 4

Completed

Conditions: Psychotic Disorders
Tobacco-Use Disorder
Schizophrenia

Interventions: Drug: bupropion SR
Behavioral: Cognitive Behavioral Group Therapy
Drug: nicotine replacement therapy

First Posted Date: 2006-03-27

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 51

Registration Number: NCT00307203

Locations: 🇺🇸
Freedom Trail Clinic, Boston, Massachusetts, United States

Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence

Phase 3

Completed

Conditions: Alcohol-Related Disorders
Smoking Cessation

Interventions: Drug: placebo
Drug: Bupropion

First Posted Date: 2006-03-20

Last Posted Date: 2017-05-15

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 143

Registration Number: NCT00304707

Locations: 🇺🇸
ENRM Veterans Hospital, Bedford, Massachusetts, United States

Step'n Out: A Multisite Trial of Collaborative Behavioral Management for Drug-Involved Parolees

Not Applicable

Conditions: Substance-Related Disorders

First Posted Date: 2006-03-14

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 420

Registration Number: NCT00302575

Locations: 🇺🇸
Connecticut Deptartment of Mental Health & Addiction Services, Hartford, Connecticut, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

and more 2 locations

Serotonin, Impulsivity, and Cocaine Dependence Treatment

Phase 2

Completed

Conditions: Cocaine Dependence

First Posted Date: 2006-02-28

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 120

Registration Number: NCT00297505

Locations: 🇺🇸
University of Texas - Houston Health Science Center, Houston, Texas, United States

Strategies to Help Adult ED Patients Quit Smoking

Not Applicable

Completed

Conditions: Tobacco Use

First Posted Date: 2006-02-28

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 336

Registration Number: NCT00297466

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Implementing Tobacco Control in Dental Practice

Phase 3

Conditions: Smoking

First Posted Date: 2006-02-28

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 2800

Registration Number: NCT00297700

Locations: 🇺🇸
Center for Health Research, Portland, Oregon, United States

Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients

Phase 1

Completed

Conditions: Opioid-Related Disorders

Interventions: Drug: Clonidine
Drug: Placebo

First Posted Date: 2006-02-23

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 208

Registration Number: NCT00295308

Locations: 🇺🇸
National Institute on Drug Abuse, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy